Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD‑1 or PD‑L1 inhibitor in the unresectable or metastatic treatment setting'.

The dosage schedule is available in the summary of product characteristics for erdafitinib.

The list price for erdafitinib is £12,750 per 28 days (excluding VAT; company submission).

The company has a commercial arrangement. This makes erdafitinib available to the NHS with a discount. The size of the discount is commercial in confidence.